Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Long-Term Dynamics of Three Dimensional Telomere Profiles in Circulating Tumor Cells in High-Risk Prostate Cancer Patients Undergoing Androgen-Deprivation and Radiation Therapy.

Wark L, Quon H, Ong A, Drachenberg D, Rangel-Pozzo A, Mai S.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1165. doi: 10.3390/cancers11081165.

2.

Institutional review of glial tumors treated with chemotherapy: the first description of PCV-related pseudoprogression.

Sharma AM, Willcock M, Bucher O, Amaratunga T, Khan MN, Loewen SK, Quon H, Essig M, Pitz M.

Neurooncol Pract. 2019 Jan;6(1):22-29. doi: 10.1093/nop/npy012. Epub 2018 May 21.

PMID:
31385994
3.

Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials.

Alayed Y, Quon H, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Helou J, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Commisso A, Commisso K, Loblaw A.

Radiother Oncol. 2019 Jun 29;140:105-109. doi: 10.1016/j.radonc.2019.06.018. [Epub ahead of print]

PMID:
31265940
4.

Volumetric changes in pharyngeal structures following head and neck cancer chemoradiation therapy.

Hinther A, Samson N, Lau H, Quon H, Banerjee R, Lysack JT, Grendarova P, Matthews TW, Randall DR.

Laryngoscope. 2019 Jul 1. doi: 10.1002/lary.28164. [Epub ahead of print]

PMID:
31260128
5.

Radiation Oncology Device Approval in the United States and Canada.

Beers CA, Smith WL, Weppler S, Schinkel C, Quon H.

Cureus. 2019 Apr 1;11(4):e4351. doi: 10.7759/cureus.4351.

6.

Framework for the quantitative assessment of adaptive radiation therapy protocols.

Weppler S, Quon H, Banerjee R, Schinkel C, Smith W.

J Appl Clin Med Phys. 2018 Nov;19(6):26-34. doi: 10.1002/acm2.12437. Epub 2018 Aug 29.

7.

Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials.

Alayed Y, Cheung P, Pang G, Mamedov A, D'Alimonte L, Deabreu A, Commisso K, Commisso A, Zhang L, Quon HC, Musunuru HB, Helou J, Loblaw DA.

Radiother Oncol. 2018 May;127(2):213-218. doi: 10.1016/j.radonc.2018.03.005. Epub 2018 Mar 24.

PMID:
29588072
8.

Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.

Quon HC, Ong A, Cheung P, Chu W, Chung HT, Vesprini D, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Loblaw A.

Radiother Oncol. 2018 May;127(2):206-212. doi: 10.1016/j.radonc.2018.02.029. Epub 2018 Mar 15.

PMID:
29551231
9.

Targeting the Tumor: Assessing the Impact of Bladder Volume and Position on Accuracy of Radiation Delivery for Patients with Bladder Cancer.

Kochan A, Rivest R, Galloway K, Lambert P, Ong A, Koul R, Ahmed S, Bashir B, Quon H.

Cureus. 2017 Sep 1;9(9):e1638. doi: 10.7759/cureus.1638.

10.

Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?

Helou J, D'Alimonte L, Quon H, Deabreu A, Commisso K, Cheung P, Chu W, Mamedov A, Davidson M, Ravi A, Loblaw A.

Radiother Oncol. 2017 Jun;123(3):478-482. doi: 10.1016/j.radonc.2017.03.006. Epub 2017 Apr 19.

PMID:
28433413
11.

Dynamics of three-dimensional telomere profiles of circulating tumor cells in patients with high-risk prostate cancer who are undergoing androgen deprivation and radiation therapies.

Wark L, Klonisch T, Awe J, LeClerc C, Dyck B, Quon H, Mai S.

Urol Oncol. 2017 Mar;35(3):112.e1-112.e11. doi: 10.1016/j.urolonc.2016.10.018. Epub 2016 Dec 10.

12.

Prospective swallowing outcomes after IMRT for oropharyngeal cancer: Dosimetric correlations in a population-based cohort.

Guo GZ, Sutherland KR, Myers C, Lambert P, Loewen SK, Quon HC.

Oral Oncol. 2016 Oct;61:135-41. doi: 10.1016/j.oraloncology.2016.08.021. Epub 2016 Sep 12.

PMID:
27688116
13.

Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials.

Quon HC, Musunuru HB, Cheung P, Pang G, Mamedov A, D'Alimonte L, Deabreu A, Zhang L, Loblaw A.

Front Oncol. 2016 Aug 29;6:185. doi: 10.3389/fonc.2016.00185. eCollection 2016.

14.

Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials.

Musunuru HB, Quon H, Davidson M, Cheung P, Zhang L, D'Alimonte L, Deabreu A, Mamedov A, Loblaw A.

Radiother Oncol. 2016 Jan;118(1):112-7. doi: 10.1016/j.radonc.2015.12.020. Epub 2016 Jan 12.

PMID:
26796591
15.

Impact of feeding tubes on prospective functional outcomes in patients with locally advanced head and neck cancer undergoing radiation therapy.

Quon H, Myers C, Lambert P, Butler J, Abdoh A, Stimpson R, Duerksen DR, Campbell-Enns H, Martens A.

Pract Radiat Oncol. 2015 Nov-Dec;5(6):e567-73. doi: 10.1016/j.prro.2015.05.007. Epub 2015 Jul 26.

PMID:
26215583
16.

The impact of fellowship training on pathological outcomes following radical prostatectomy: a population based analysis.

Nayak JG, Drachenberg DE, Mau E, Suderman D, Bucher O, Lambert P, Quon H.

BMC Urol. 2014 Oct 23;14:82. doi: 10.1186/1471-2490-14-82.

17.

Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.

Lecavalier-Barsoum M, Quon H, Abdulkarim B.

Cochrane Database Syst Rev. 2014 May 15;(5):CD007104. doi: 10.1002/14651858.CD007104.pub2. Review.

PMID:
24833028
18.

Population-based referrals for adjuvant radiotherapy after radical prostatectomy in men with prostate cancer: impact of randomized trials.

Quon H, Suderman D, Guilbert K, Lambert P, Bucher O, Ong A, Chowdhury A.

Clin Genitourin Cancer. 2014 Feb;12(1):e1-5.

PMID:
24571005
19.

Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes.

Loblaw A, Cheung P, D'Alimonte L, Deabreu A, Mamedov A, Zhang L, Tang C, Quon H, Jain S, Pang G, Nam R.

Radiother Oncol. 2013 May;107(2):153-8. doi: 10.1016/j.radonc.2013.03.022. Epub 2013 May 3.

PMID:
23647750
20.

Supplemental Content

Loading ...
Support Center